Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas
Recruiting
Observational Study
Glioma
Radiotherapy; Complications
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 320 (estimated)
- Sponsor
- Erasmus Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Rationale:
Proton beam therapy has recently become available for the treatment of patients with WHO grade 2 and 3 IDH mutated (IDHmt) glioma in the Netherlands. The dose distributions associated with proton therapy have substantially reduced the volume of the normal brain irradiated with low and intermediate radiotherapy doses. Whether this impacts rates of progressive disease or safety issues an…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histopathologically confirmed WHO grade 2 or grade WHO 3 IDHmt glioma
* Treatment with radiotherapy delivered between 1 of January 2018 and completed before or on the 30th of June 2022
* Treatment with chemotherapy delivered after radiotherapy (PCV or Temozolomide)
* Age ≥ 18 …
Contacts